Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

NCT00066326 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: imatinib mesylate
DRUG: tanespimycin

Sponsor

Barbara Ann Karmanos Cancer Institute

Collaborators

[object Object]